GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (TSXV:NRX) » Definitions » Cash, Cash Equivalents, Marketable Securities

NurExone Biologic (TSXV:NRX) Cash, Cash Equivalents, Marketable Securities : C$0.84 Mil (As of Mar. 2025)


View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic Cash, Cash Equivalents, Marketable Securities?

NurExone Biologic's quarterly cash, cash equivalents, marketable securities declined from Sep. 2024 (C$3.42 Mil) to Dec. 2024 (C$1.00 Mil) but then stayed the same from Dec. 2024 (C$1.00 Mil) to Mar. 2025 (C$0.84 Mil).

NurExone Biologic's annual cash, cash equivalents, marketable securities declined from Dec. 2022 (C$3.35 Mil) to Dec. 2023 (C$0.73 Mil) but then increased from Dec. 2023 (C$0.73 Mil) to Dec. 2024 (C$1.00 Mil).


NurExone Biologic Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for NurExone Biologic's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Cash, Cash Equivalents, Marketable Securities Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Cash, Cash Equivalents, Marketable Securities
2.83 3.35 0.73 1.00

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.41 3.27 3.42 1.00 0.84

NurExone Biologic Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


NurExone Biologic  (TSXV:NRX) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


NurExone Biologic Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


NurExone Biologic Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (TSXV:NRX) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
Address
1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.
Executives
James Angus Wilson (bilkstys-) Richardson 10% Security Holder, Director, Senior Officer

NurExone Biologic Headlines

No Headlines